# A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain

Source: https://onco.cc/trials/nct07029737/  
OnCo record `nct07029737` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Acalabrutinib, Rituximab in mantle cell lymphoma, run by AstraZeneca, now recruiting.

## Summary

A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain is a phase 2 interventional study registered as NCT07029737 by AstraZeneca, with 55 participants planned, started 2025-09-05 and due to reach its primary completion in 2027-12-31. Interventions recorded: Acalabrutinib + R-CHOP standard of care, Acalabrutinib combination with Rituximab, Acalabrutinib monotherapy. Conditions listed: Mantle-cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07029737
- Phase: 2
- Setting: The SOUND-MCL Study: A Single-arm, Open-label, Multicenter, Phase II Study of Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
- Sponsor: AstraZeneca
- Enrolled: 55

## Sources

- ClinicalTrials.gov NCT07029737: https://clinicaltrials.gov/study/NCT07029737

## Connected records

- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [Rituximab](https://onco.cc/drugs/rituximab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07029737.json